← Back to all media
Beware the pitfalls for non-specialist investors in the #biotechnology space warns International Biotech Trust
There are many ways a biotech company can succeed, but there are many more ways it can fail. Since most early-stage drug development projects will unfortunately fail, investors need to be able to spot the substandard ones and, crucially, avoid the mediocre ones that can linger on to become costly lessons.
Published on 14th May 2021